The term vasculogenic mimicry describes the formation of fluid‐conducting channels by
highly invasive and genetically dysregulated tumor cells. Two distinctive types of …

Background Trastuzumab is a drug that targets the receptor tyrosine kinase HER2 and is
essential for the treatment of HER2-positive breast cancer. Resistance to the drug leads to …

Vasculogenic mimicry (VM), a newly defined pattern of tumor blood supply, describes the
functional plasticity of aggressive cancer cells that form vascular networks. In our previous …

Triple-negative breast cancer (TNBC) is associated with epithelial-mesenchymal transition
(EMT) and the phenotype of breast cancer stem cells (CSCs). Vasculogenic mimicry (VM) is …

Abstract “Vasculogenic mimicry (VM)”, is a term that describes the unique ability of highly
aggressive tumor cells to express a multipotent, stem cell-like phenotype, and form a pattern …

Increased vasculogenesis must occur for tumors to develop and be maintained. Normally,
vascular networks are composed of tube structures lined with endothelial cells. However, the …

Anti-angiogenic therapy has shown promising but insufficient efficacy on gliomas. Recent
studies suggest that vasculogenic mimicry (VM), or the formation of non-endothelial, tumor …

Glioblastoma (GBM) is a highly angiogenic malignancy that is resistant to standard therapy;
neo-formed vessels of this aggressive malignancy are thought to arise by sprouting of pre …

Hepatocellular carcinoma (HCC) is a typical hyper-vascular solid tumor; aberrantly rich in
tumor vascular network contributes to its malignancy. Conventional anti-angiogenic …

Vasculogenic mimicry (VM), a microvascular channel made up of nonendothelial cells, has
been accepted as a new model of neovascularization in aggressive tumors, owning to the …